|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-3.28/-3.47
|
企业价值
1.02B
|
资产负债 |
每股账面净值
12.04
|
现金流量 |
现金流量率
--
|
损益表 |
收益
26.98M
|
每股收益
0.36
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2025/01/11 16:27 EST
同行比较之报价最少15分钟延迟
业务概览
|
|||
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. |